- Home
- ACIU vs FCAP Comparison
ACIU vs FCAP Comparison
Compare ACIU & FCAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- FCAP
- Stock Information
- Founded
- ACIU 2003
- FCAP 1891
- Country
- ACIU Switzerland
- FCAP United States
- Employees
- ACIU N/A
- FCAP N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- FCAP Savings Institutions
- Sector
- ACIU Health Care
- FCAP Finance
- Exchange
- ACIU Nasdaq
- FCAP Nasdaq
- Market Cap
- ACIU 189.1M
- FCAP 161.2M
- IPO Year
- ACIU 2016
- FCAP 1999
- Fundamental
- Price
- ACIU $2.07
- FCAP $39.39
- Analyst Decision
- ACIU Strong Buy
- FCAP
- Analyst Count
- ACIU 1
- FCAP 0
- Target Price
- ACIU $12.00
- FCAP N/A
- AVG Volume (30 Days)
- ACIU 125.1K
- FCAP 31.8K
- Earning Date
- ACIU 08-05-2025
- FCAP 07-25-2025
- Dividend Yield
- ACIU N/A
- FCAP 2.89%
- EPS Growth
- ACIU N/A
- FCAP 2.61
- EPS
- ACIU N/A
- FCAP 3.65
- Revenue
- ACIU $32,014,254.00
- FCAP $42,869,000.00
- Revenue This Year
- ACIU N/A
- FCAP N/A
- Revenue Next Year
- ACIU $533.21
- FCAP N/A
- P/E Ratio
- ACIU N/A
- FCAP $10.98
- Revenue Growth
- ACIU 91.20
- FCAP 6.35
- 52 Week Low
- ACIU $1.43
- FCAP $28.50
- 52 Week High
- ACIU $4.26
- FCAP $53.85
- Technical
- Relative Strength Index (RSI)
- ACIU 55.57
- FCAP 41.56
- Support Level
- ACIU $2.00
- FCAP $39.00
- Resistance Level
- ACIU $2.15
- FCAP $44.48
- Average True Range (ATR)
- ACIU 0.13
- FCAP 1.73
- MACD
- ACIU -0.01
- FCAP -0.17
- Stochastic Oscillator
- ACIU 80.92
- FCAP 33.82
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About FCAP First Capital Inc.
First Capital Inc is the financial holding company of First Harrison Bank. Through its subsidiary, it operates as a federally-chartered savings bank that provides banking services to individuals and business customers across locations in America. The bank offers various loans which include residential loans, construction loans, commercial real estate loans and commercial business loans. It also provides consumer loans such as home equity and second mortgage loans, and automobile and truck loans.